Core Viewpoint - The article highlights the collective rise of the MicroPort group stocks following the announcement of MicroPort Medical's restructuring of its cardiac rhythm management business, which aims to alleviate pressure related to meeting listing standards [1] Group 1: Stock Performance - MicroPort Medical (00853) increased by 8.47%, reaching HKD 14.21 [1] - HeartLink Medical-B (02160) rose by 4.55%, reaching HKD 1.38 [1] - MicroPort Robotics-B (02252) saw a 4.28% increase, reaching HKD 28.26 [1] - MicroPort Neuroscience (02172) grew by 2.88%, reaching HKD 12.52 [1] Group 2: Business Restructuring - MicroPort Medical announced the restructuring of its cardiac rhythm management business, with its subsidiary MicroPort HeartLink planning to merge with CRM Cayman [1] - Upon completion of the merger, CRM Cayman will become a wholly-owned subsidiary of MicroPort HeartLink, focusing on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is reported to be USD 680 million [1] Group 3: Ownership and Investment - MicroPort Medical currently holds a 46.12% stake in HeartLink Medical and a 50.13% stake in CRM Cayman [1] - In July 2021, Hillhouse Capital, along with CPE and Springhill, invested USD 300 million in MicroPort's cardiac rhythm management subsidiary, acquiring a 26.3% stake [1] - There is an agreement that if CRM Cayman does not achieve a qualified listing and a market value of at least USD 1.5 billion by July 17, 2025, MicroPort must repurchase all shares at an annualized return of 8% [1]
港股异动 | 微创系集体上涨 微创医疗宣布重组心律管理业务 打造心脏病综合解决方案平台